

英文論文

(原著+症例報告)

1. Furue M, Iida K, Imaji M, Nakahara T. Microbiome analysis of forehead skin in patients with atopic dermatitis and healthy subjects: Implication of *Staphylococcus* and *Corynebacterium*. *J Dermatol*. 2018 Jul;45(7):876-877.
2. Furue M, Takemura M, Nishio K, Sato Y, Nagata S, Kan N, Suenaga A, Furue K, Yoshida M, Konishi S, Tsuji G. Immunohistological Localization of Peroxisome Proliferator-Activated Receptor α and γ in Human Sebaceous Glands. *Fukuoka Igaku Zasshi*. 2016 Nov;107(11):199-203.
3. Mitoma C, Furue M. Overexpression of S100A7 protein is an integral part of abnormal epidermal differentiation in cornoid lamella of porokeratosis. *Int J Dermatol*. 2018 Feb;57(2):e7-e9.
4. Takeuchi S, Oba J, Esaki H, Furue M. Non-corticosteroid adherence and itch severity influence perception of itch in atopic dermatitis. *J Dermatol*. 2018 Feb;45(2):158-164.
5. Nakahara T, Konishi S, Yasukochi Y, Esaki H, Tsuji G, Kido-Nakahara M, Furue M. Thrombocytopenia in a psoriatic patient sequentially treated with adalimumab, secukinumab and ustekinumab. *J Dermatol*. 2018 Oct 24. doi: 10.1111/1346-8138.14681. [Epub ahead of print]
6. Nakahara T, Kido-Nakahara M, Ohno F, Ulzii D, Chiba T, Tsuji G, Furue M. The pruritogenic mediator endothelin-1 shifts the dendritic cell-T-cell response toward Th17/Th1 polarization. *Allergy*. 2018 Feb;73(2):511-515.
7. Kido-Nakahara M, Nakahara T, Furusyo N, Shimoda S, Kotoh K, Kato M, Hayashi J, Koyanagi T, Furue M. Pruritus in Chronic Liver Disease: A Questionnaire Survey on 216 Patients. *Acta Derm Venereol*. 2018 Oct 11. doi: 10.2340/00015555-3064. [Epub ahead of print]
8. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnem J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. *JCO Precis Oncol*. Epub 2018 Jun 5. PMID: 30094412.
9. Chiba T, Nakahara T, Fujishima K, Hashimoto-Hachiya A, Furue M. Epidermal barrier disruption by 9-hydroxy-10E,12Z-octadecadienoic acid in human keratinocytes. *J Dermatol*. 2018 Jun;45(6):746-747.

10. Chiba T, Koga H, Kimura N, Murata M, Jinnai S, Suenaga A, Kohda F, Furue M. Clinical Condition and Management of 114 Mamushi (*Gloydius blomhoffii*) Bites in a General Hospital in Japan. *Intern Med*. 2018 Apr 15;57(8):1075-1080.
11. Chiba T, Ishida N, Kohda F, Furue M. Air exposure may be associated with the histological differentiation of a cultured epidermal autograft (JACE). *Australas J Dermatol*. 2018 Aug;59(3):e244-e246.
12. Kudo K, Masuda A, Mizobe T, Kihara J, Onoyama S, Furuno K, Furue M. Bullous artificial dermatitis due to aerosol sprays masquerading as fixed drug eruption. *J Dermatol*. 2018 Dec 19. doi: 10.1111/1346-8138.14729.
13. Fuyuno Y, Uchi H, Yasumatsu M, Morino-Koga S, Tanaka Y, Mitoma C, Furue M. Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes. *Oxid Med Cell Longev*. 2018 Feb 14;2018:9524657. doi: 10.1155/2018/9524657
14. Nagae K, Uchi H, Morino-Koga S, Tanaka Y, Oda M, Furue M. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K/Akt pathway in keratinocytes. *Diabetes Res Clin Pract*. 2018 Oct 25;146:155-161.
15. Mitamura Y, Murai M, Mitoma C, Furue M. NRF2 Activation Inhibits Both TGF- β 1- and IL-13-Mediated Periostin Expression in Fibroblasts: Benefit of Cinnamaldehyde for Antifibrotic Treatment. *Oxid Med Cell Longev*. 2018 Aug 7;2018:2475047.
16. Mitamura Y, Nunomura S, Nanri Y, Arima K, Yoshihara T, Komiya K, Fukuda S, Takatori H, Nakajima H, Furue M, Izuhara K. Hierarchical control of interleukin 13 (IL-13) signals in lung fibroblasts by STAT6 and SOX11. *J Biol Chem*. 2018 Sep 21;293(38):14646-14658.
17. Mitamura Y, Nunomura S, Nanri Y, Ogawa M, Yoshihara T, Masuoka M, Tsuji G, Nakahara T, Hashimoto-Hachiya A, Conway SJ, Furue M, Izuhara K. The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. *Allergy*. 2018 Sep;73(9):1881-1891.
18. Kaku-Ito Y, Ito T, Tsuji G, Nakahara T, Hagihara A, Furue M, Uchi H. Evaluation of mapping biopsies for extramammary Paget disease: A retrospective study. *J Am Acad Dermatol*. 2018 Jun;78(6):1171-1177
19. Kiyomatsu-Oda M, Uchi H, Morino-Koga S, Furue M. Protective role of 6-formylindolo[3,2-b]carbazole (FICZ), an endogenous ligand for arylhydrocarbon receptor, in chronic mite-induced dermatitis. *J Dermatol Sci*. 2018 Jun;90(3):284-294.

20. Murata M, Chiba T, Kohda F, Furue M. Instant Noodle as a Major Cause of Pediatric Burns. *Dermatologica Sinica*. 2018 Sep;36(3):167-168.
21. Wada N, Uchi H, Furue M. Trichophytic closure for cicatricial alopecia on the scalp. In printing
22. Wada N, Uchi H, Furue M. Case of angiosarcoma of the scalp successfully controlled by eribulin. *J Dermatol*. 2018 Jan;45(1):116-117.
23. Wada N, Uchi H, Furue M. Case of deep vein thrombosis in a patient with advanced malignant melanoma treated with dabrafenib and trametinib. *J Dermatol*. 2018 Jul;45(7):e173-e174.
24. Take N, Nakahara T, Kido-Nakahara M, Furue M. Three cases of adult-onset atopic dermatitis after hematopoietic stem cell transplantation. *Allergol Int*. 2018 Oct;67(4):529-531.
25. Take N, Mitoma C, Furue M. Necrobiosis lipoidica with mucin deposition in a patient with autoimmune thyroiditis. *J Dermatol*. 2018 Jul;45(7):e193-e194.
26. Murai M, Yamamura K, Hashimoto-Hachiya A, Tsuji G, Furue M, Mitoma C. Tryptophan photo-product FICZ upregulates AHR/MEK/ERK-mediated MMP1 expression: Implications in anti-fibrotic phototherapy. *J Dermatol Sci*. 2018 Jul;91(1):97-103.
27. Murai M, Tsuji G, Hashimoto-Hachiya A, Kawakami Y, Furue M, Mitoma C. An endogenous tryptophan photo-product, FICZ, is potentially involved in photo-aging by reducing TGF- β -regulated collagen homeostasis. *J Dermatol Sci*. 2018 Jan;89(1):19-26.
28. Inatomi Y, Yoshida S, Kamizono K, Hanada M, Yasumatsu R, Kadota H. Successful treatment of severe facial lymphedema by lymphovenous anastomosis. *Head & Neck*. 2018 May 13. 40(7):E73-76
29. Inatomi Y, Kadota H, Kaku K, Sonoda H, Tanoue Y, Shiose A. Omental and deep inferior epigastric artery perforator flap coverage after heart transplantation to manage wide left ventricular assist device exposure with pocket infection. *J Art Org*. 2018 Oct 22; 21(4): 466-470.
30. Kimura N, Takeshita H, Kai T, Inoue Y, Furue M. Schnitzler's syndrome: A female elderly case presenting intractable non-pruritic febrile urticarial rash. *Asian Pac J Allergy Immunol*. 2018 Dec 9. doi: 10.12932/AP-150818-0394.
31. Maehara E, Kido-Nakahara M, Ito T, Uchi H, Furue M. Darier's sign in urticaria pigmentosa-significance of perivascular eosinophilic infiltration. *Allergol Int*. 2018 Oct;67(4):532-534.

32. Ichiki T, Wada M, Yasukouchi Y, Nakahara T, Mitoma C, Uchi H, Nishizaki A, Mukai Y, Furue M. Crystallization granuloma by nifekalant hydrochloride infusion. *Geriatr Gerontol Int*. 2018 Jul;18(7):1133-1134.
33. Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. *J Dermatol*. 2018 Jun 15. doi: 10.1111/1346-8138.14516.
34. Takemura M, Nakahara T, Hashimoto-Hachiya A, Furue M, Tsuji G. Glyteer, Soybean Tar, Impairs IL-4/Stat6 Signaling in Murine Bone Marrow-Derived Dendritic Cells: The Basis of Its Therapeutic Effect on Atopic Dermatitis. *Int J Mol Sci*. 2018 Apr 12;19(4). pii: E1169.
35. Tanaka Y, Uchi H, Hashimoto-Hachiya A, Furue M. Tryptophan Photoproduct FICZ Upregulates IL1A, IL1B, and IL6 Expression via Oxidative Stress in Keratinocytes. *Oxid Med Cell Longev*. 2018 Nov 25;2018:9298052. doi: 10.1155/2018/9298052. eCollection 2018.
36. Hashimoto-Hachiya A, Tsuji G, Murai M, Yan X, Furue M. Upregulation of FLG, LOR, and IVL Expression by *Rhodiola crenulata* Root Extract via Aryl Hydrocarbon Receptor: Differential Involvement of OVOL1. *Int J Mol Sci*. 2018 Jun 4;19(6). pii: E1654.
37. Akahane M, Matsumoto S, Kanagawa Y, Mitoma C, Uchi H, Yoshimura T, Furue M, Imamura T. Long-Term Health Effects of PCBs and Related Compounds: A Comparative Analysis of Patients Suffering from Yusho and the General Population. *Arch Environ Contam Toxicol*. 2018 Feb;74(2):203-217.
38. Akamine S, Sagata N, Sakai Y, Kato TA, Nakahara T, Matsushita Y, Togao O, Hiwatashi A, Sanefuji M, Ishizaki Y, Torisu H, Saitsu H, Matsumoto N, Hara T, Sawa A, Kano S, Furue M, Kanba S, Shaw CA, Ohga S. Early-onset epileptic encephalopathy and severe developmental delay in an association with de novo double mutations in NF1 and MAGEL2. *Epilepsia Open*. 2017 Nov 23;3(1):81-85.
39. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette J, Peng DH, Ungewiss C, Roybal JD, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, V Heymach J, Qin FX, Gibbons DL. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. *Cancer Discov*. 2018 Sep;8(9):1156-1175. PMID: 30012853.
40. Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R,

- Aoki M, Imafuku K, Okuhira H, Wada N, Irie H, Hidaka T, Hashimoto A, Aiba S. Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma. *Front Oncol.* 2018 Nov 19;8:530.
41. Fujimura T, Sato Y, Tanita K, Kambayashi Y, Otsuka A, Fujisawa Y, Yoshino K, Matsushita S, Funakoshi T, Hata H, Yamamoto Y, Uchi H, Nonomura Y, Tanaka R, Aoki M, Imafuku K, Okuhira H, Furudate S, Hidaka T, Aiba S. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. *Oncotarget.* 2018 Feb 15;9(21):15542-15551.
 42. Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, Nagai K, Ishida Y, Nakamura Y, Furudate S, Yamamura K, Imafuku K, Yamamoto Y. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. *J Dermatol Sci.* 2018 Jan;89(1):60-66.
 43. Grinich EE, Schmitt J, Küster D, Spuls PI, Williams HC, Chalmers JR, Thomas KS, Apfelbacher C, Prinsen CAC, Furue M, Stuart B, Carter B, Simpson EL. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. *Br J Dermatol.* 2018 Aug;179(2):540-541.
 44. Hirakawa S, Miyawaki T, Hori T, Kajiwara J, Katsuki S, Hirano M, Yoshinouchi Y, Iwata H, Mitoma C, Furue M. Accumulation properties of polychlorinated biphenyl congeners in Yusho patients and prediction of their cytochrome P450-dependent metabolism by in silico analysis. *Environ Sci Pollut Res Int.* 2018 Jun;25(17):16455-16463.
 45. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara R, Nakano M, Ruzicka T. Nemoalizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. *J Allergy Clin Immunol.* 2018 Oct;142(4):1121-1130.
 46. Kawahara S, Mitoma C, Murai M, Furue M. Acquired perforating collagenosis in a non-diabetic patient with advanced prostate carcinoma: A review of perforating dermatosis associated with malignancy. *J Dermatol.* 2018 Aug;45(8):e219-e220.
 47. Kitahara Y, Hojo S, Nomoto M, Onozuka D, Furue M, Hagihara A. Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis. *J Dermatolog Treat.* 2018 Nov 19:1-5.

48. Kondo H, Tanio K, Nagaura Y, Nagayoshi M, Mitoma C, Furue M, Maeda T. Sleep disorders among Yusho patients highly intoxicated with dioxin-related compounds: A 140-case series. *Environ Res.* 2018 Oct;166:261-268.
49. McKean M*, Oba J* (*co-first authors), Ma J, Roth KG, Wang WL, Macedo MP, Carapeto F, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT- mutant Metastatic Melanoma. *J Invest Dermatol.* Accepted for publication (in press, accepted on October 14, 2018)
50. Miyawaki T, Sugihara M, Hirakawa S, Hori T, Kajiwara J, Katsuki S, Mitoma C, Furue M. Compound-specific isotopic and congener-specific analyses of polychlorinated biphenyl in the heat medium and rice oil of the Yusho incident. *Environ Sci Pollut Res Int.* 2018 Jun;25(17):16464-16471.
51. Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, Takatsuka S, Koga H, Wada N, Minami H, Hatsumichi M, Asada S, Namba Y, Yamazaki N. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. *Eur J Cancer.* 2018 Nov 14;105:114-126.
52. Shiratori-Hayashi M, Hasegawa A, Toyonaga H, Andoh T, Nakahara T, Kido-Nakahara M, Furue M, Kuraishi Y, Inoue K, Dong X, Tsuda M. Role of P2X3 receptors in scratching behavior in mouse models. *J Allergy Clin Immunol.* 2018 Nov 16. pii: S0091-6749(18)31604-X. doi: 10.1016/j.jaci.2018.10.053. [Epub ahead of print]
53. Yamada Y, Kinoshita I, Kenichi K, Yamamoto H, Iwasaki T, Otsuka H, Yoshimoto M, Ishihara S, Toda Y, Kuma Y, Setsu N, Koga Y, Honda Y, Inoue T, Yanai H, Yamashita K, Ito I, Takahashi M, Ohga S, Furue M, Nakashima Y, Oda Y. Histopathological and genetic review of phosphaturic mesenchymal tumours, mixed connective tissue variant. *Histopathology.* 2018 Feb;72(3):460-471.
54. Yamaguchi K, Mishima K, Ohmura H, Hanamura F, Ito M, Nakano M, Tsuchihashi K, Ota SI, Wada N, Uchi H, Ariyama H, Kusaba H, Niuro H, Akashi K, Baba E. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody. *Cancer Sci.* 2018 Oct;109(10):3032-3042.
55. Yano S, Ashida K, Nagata H, Ohe K, Wada N, Takeichi Y, Hanada Y, Ibayashi Y, Wang L, Sakamoto S, Sakamoto R, Uchi H, Shiratsuchi M, Furue M, Nomura M, Ogawa Y. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is

frequently evoked in Japanese patients with malignant melanoma. *BMC Endocr Disord.* 2018 Jun 8;18(1):36.

(総説)

1. Furue M, Uchi H, Mitoma C, Hashimoto-Hachiya A, Tanaka Y, Ito T, Tsuji G. Implications of tryptophan photoproduct FICZ in oxidative stress and terminal differentiation of keratinocytes. *G Ital Dermatol Venereol.* 2018 Jul 20. doi: 10.23736/S0392-0488.18.06132-1.
2. Furue M, Fuyuno Y, Mitoma C, Uchi H, Tsuji G. Therapeutic Agents with AHR Inhibiting and NRF2 Activating Activity for Managing Chloracne. *Antioxidants (Basel).* 2018 Jul 13;7(7). pii: E90. doi: 10.3390/antiox7070090.
3. Furue M, Hashimoto-Hachiya A, Tsuji G. Antioxidative Phytochemicals Accelerate Epidermal Terminal Differentiation via the AHR-OVOL1 Pathway: Implications for Atopic Dermatitis. *Acta Derm Venereol.* 2018 Nov 5;98(10):918-923. doi: 10.2340/00015555-3003.
4. Furue M, Ito T, Wada N, Wada M, Kadono T, Uchi H. Melanoma and Immune Checkpoint Inhibitors. *Curr Oncol Rep.* 2018 Mar 23;20(3):29. doi: 10.1007/s11912-018-0676-z.
5. Uchi H. Merkel Cell Carcinoma: An Update and Immunotherapy. *Front Oncol.* 2018 Mar 6;8:48.
6. Mitoma C, Uchi H, Tsukimori K, Todaka T, Kajiwara J, Shimose T, Akahane M, Imamura T, Furue M. Current state of yusho and prospects for therapeutic strategies. *Environ Sci Pollut Res Int.* 2018 Jun;25(17):16472-16480.
7. Nakahara T, Morimoto H, Murakami N, Furue M. Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis. *Pediatr Allergy Immunol.* 2018 May;29(3):233-238.
8. Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. *Immunol Allergy Clin North Am.* 2017;37(1):113-122.
9. Tsuji G, Ito T, Chiba T, Mitoma C, Nakahara T, Uchi H, Furue M. The role of the OVOL1-OVOL2 axis in normal and diseased human skin. *J Dermatol Sci.* 2018 Jun;90(3):227-231.
10. Ito T, Kaku-Ito Y, Furue M. The diagnosis and management of extramammary Paget's disease. *Expert Rev Anticancer Ther.* 2018 Jun;18(6):543-553.

11. Furue K, Ito T, Furue M. Differential efficacy of biologic treatments targeting the TNF- α /IL-23/IL-17 axis in psoriasis and psoriatic arthritis. *Cytokine*. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.
12. Furue K, Mitoma C, Tsuji G, Furue M. Protective role of peroxisome proliferator-activated receptor α agonists in skin barrier and inflammation. *Immunobiology*. 2018 Mar;223(3):327-330. doi: 10.1016/j.imbio.2017.10.047.
13. Furue K, Ito T, Tsuji G, Kadono T, Nakahara T, Furue M. Autoimmunity and autoimmune co-morbidities in psoriasis. *Immunology*. 2018 May;154(1):21-27.
14. Furue K, Yamamura K, Tsuji G, Mitoma C, Uchi H, Nakahara T, Kido-Nakahara M, Kadono T, Furue M. Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis. *Acta Derm Venereol*. 2018 Jan 12;98(1):5-13.

邦文論文

(原著+症例報告)

1. 古江増隆、坂本佳子、立花由紀子、和田美香、木村七絵、宮崎敬子、樋渡千佳、濱田正美、従来型高機能エアマットレス抵抗性の褥瘡—新規体圧分散型高機能エアマットレスへの変更が奏功した2例—、臨床と研究 95(7):781-783, 2018
2. 吉田舞子、三苫千景、中原真希子、内博史、古江増隆. Pseudoxanthoma elasticum-like papillary dermal elastolysis. *西日本皮膚科* in press
3. 磯谷 智世, 木村 七絵, 執行 あかり, 桐生 美麿, 古江 増隆. 片側性 Darier 病の1例. *西日本皮膚科* 2018; 80(2): 113-116.
4. 磯谷 智世, 執行 あかり, 桐生 美麿, 古江 増隆. 超音波検査が有用であった Solid-cystic Hidradenoma. *西日本皮膚科* 2018; 80(2): 95-96.
5. 園山 浩子、西尾 紀一郎、増野 年彦. ドパミン塩酸塩の血管外漏出により皮膚壊疽をきたし下腿切断に至った1例. *皮膚科の臨床* 2018.60(11):1749-1752.
6. 和田麻衣子, 内 博史, 古江 増隆. 妊娠を契機に増大した母斑細胞母斑. *西日本皮膚科* 80 ; 1-2, 2018.
7. 村田真帆、千葉貴人、幸田太.小児に多いインスタントヌードル関連熱傷.臨床皮膚科 増刊号 2018;72(5):149-151
8. 武 信肇, 中原 真希子, 中原 剛士, 内 博史, 古江 増隆.有棘細胞癌、Bowen 病が多発した表在播種型汗孔角化症の1例.西日本皮膚科 79 巻6号 Page569-573
9. 木村七絵, 占部和敬, 古江増隆. 免疫抑制治療中の SLE 患者に生じた再発性水痘. *西日本皮膚科* 80 ; 354-357, 2018

10. 坂本佳子, 菊池智子, 古江増隆. 特異な臨床像を呈し、DDS が奏効した Behcet 病. 皮膚病診療, 40:1035-1038,2018
11. 前原恵里子, 三苦 千景, 高松 紘子, 原田 佳代, 和田 尚子, 松田 知与, 石田 倫子, 今山 修平, 占部 和敬. ワルファリン併用により症状が消失した難治性慢性蕁麻疹の 1 例. 西日本皮膚科 80;15-19,2 月 2018
12. 松田知与, 原口祐子, 菊池智子, 伏見文良, 山田裕一, 小田義直, 古江増隆. Solitary fibrous tumor の 1 例. 西日本皮膚科 80:450-454,2018
13. 森岡 友佳, 辻 学, 伊東 孝通, 永江 航之介, 溝手 政博, 中原 剛士, 三苦 千景, 内 博史, 山田 裕一, 小田 義直, 古江 増隆.隆起性皮膚線維肉腫より生じたと考えられた線維肉腫(図説).西日本皮膚科 79 卷 4 号 Page337-338
14. 一木 稔生, 辻 学, 永江 航之介, 和田 麻衣子, 増田 禎一, 永瀬 浩太郎, 内 博史, 古江 増隆 臀部に発症した Merkel 細胞癌の 1 例 西日本皮膚科 (0386-9784)80 卷 3 号 Page219-223
15. 古江和久, 古江増隆.【そう痒研究の最近の進展】IL-31/IL-31 receptor シグナルとそう痒 アトピー性皮膚炎の痒み(解説/特集).臨床免疫・アレルギー科 (1881-1930)69 卷 4 号 Page348-355(2018.04)
16. 矢野温子, 三苦千景, 永江航之介, 内 博史、古江増隆. 頬部に生じた papular elastosis.西日本皮膚科 図説

(総説)

1. 中原 剛士.アトピー性皮膚炎の治療 診療ガイドラインも含めて.アレルギーの臨床 38 卷 11 号 Page1027-1030, 2018
2. 中原 剛士.高齢者の臓器別疾患 皮膚疾患 皮膚そう痒症.日本臨床 76 卷増刊 7 老年医学(下) Page157-161, 2018
3. 中原 剛士. 感覚器疾患の治療 一般臨床における外用薬の使い方 皮膚外用薬.日本医師会雑誌 147 卷特別 1 Page S304, 2018
4. 中原 剛士, 古江 増隆.アトピー性皮膚炎治療の問題点 なぜ患者満足度は低いのか? . Progress in Medicine 38 卷 5 号 Page477-482, 2018
5. 中原剛士. ストップ・ザ・マーチ！ アトピー性皮膚炎 —スキンケアの実際.MB デルマ No265 9-17, 2018
6. 中原真希子, 古江増隆. かゆみの評価と治療効果の考え方 かゆみ 治療薬を使いこなす“知識”と”ノウハウ“. 薬局 第 69 卷第6号p18-23 南山堂
7. 加藤則人, 大矢幸弘, 池田政憲、海老原全、片山一朗、佐伯秀久、下条直樹、田中暁生、中原剛士、長尾みづほ、秀 道広、藤田雄治、藤澤隆夫、二村昌

樹、益田浩司、室田浩之、山本貴和子.アトピー性皮膚炎診療ガイドライン 2018.
日皮会誌:128(12), 2431-2502, 2018

8. 秀 道広、森桶 聡、福永 淳、平郡隆明、千貫祐子、猪又直子、益田浩司、谷崎英昭、中川幸延、矢上晶子、中原剛士、戸倉新樹、青島正浩、藤澤隆夫、中村陽一、堀川達弥、五十嵐敦之. 蕁麻疹診療ガイドライン 2018. 日皮会誌:128(12), 2503-2624, 2018

(著書)

1. 竹内聡. 14. 皮膚疾患 14-6 汗疱・異汗性湿疹. 1336 専門家による私の治療 2019-20 年度版 猿田享男、北村惣一郎編、日本医事新報社. 2018 in press
2. 内 博史. 日光角化症. 皮膚病診療パワーアップ 中山書店(東京). pp271-4. 2018 年.
3. Nakahara T, Furue M. Nemolizumab and atopic dermatitis: The interaction between interleukin-31 and interleukin-31 receptor as a potential therapeutic target for pruritus in patients with atopic dermatitis. Current Treatment Options in Allergy. Volume 5, p 405-414, 2018
4. 中原剛士. ざ瘡様皮疹 (顔・頭以外). 皮膚障害アトラス&マネジメント p34-35, 2018
5. 中原剛士. 臨床診断のプロセス 掻き傷が多数あるが、湿疹がない. 皮膚病診療パワーアップ p39-43, 2018
6. 辻学 今日の治療指針「結節性紅斑」医学書院 in press
7. 杉山晃子. アトピー性皮膚炎からはじまるアレルギーマーチ. アレルギーの臨床. 38(6):29-32, 2018